VRN

Context Inhibition of acyl coenzyme A:cholesterol acyltransferase (ACAT), an intra- cellular enzyme involved in cholesterol accumulation, with pactimibe was developed to assist in the prevention of cardiovascular disease. Objective To evaluate the efficacy and safety of pactimibe in inhibition of atherosclerosis. Design, Setting, and Patients A prospective, randomized, stratified, double- blind, placebo-controlled study (Carotid Atherosclerosis Progression Trial Investigat- ing Vascular ACAT Inhibition Treatment Effects [CAPTIVATE]) of 892 patients het- erozygous for familial hypercholesterolemia conducted at 40 lipid clinics in the United States, Canada, Europe, South Africa, and Israel between February 1, 2004, and De- cember 31, 2005. Study was terminated on October 26, 2005. Intervention Participants received either 100 mg/d of pactimibe (n=443) or match- ing placebo (n=438), in addition to standard lipid-lowering therapy. Main Outcome Measures Carotid atherosclerosis, assessed by ultrasound carotid intima-media thickness (CIMT), at baseline, 12, 18, and 24 months. Maximum CIMT was the primary end point and mean CIMT the secondary end point. Results Because pactimibe failed to show efficacy in the intravascular coronary ultra- sound ACTIVATE study, the CAPTIVATE study was terminated prematurely after a fol- low-up of 15 months. After 6 months of treatment with pactimibe, low-density lipo- protein cholesterol increased by 7.3% (SD, 23%) compared with 1.4% (SD, 28%) in the placebo group (P=.001). The carotid ultrasonographic scans of the 716 patients with at least 2 scans and obtained at least 40 weeks apart were analyzed. Maximum CIMT measurements did not show a pactimibe treatment effect (difference, 0.004 mm; 95% confidence interval [CI], −0.023 to 0.015 mm; P=.64); however, the less variable mean CIMT measurement revealed an increase of 0.014 mm (95% CI, −0.027 to 0.000 mm; P=.04) in patients administered pactimibe vs placebo. Major cardiovascular events (car- diovascular death, myocardial infarction, and stroke) occurred more often in patients administered pactimibe vs placebo (10/443 [2.3%] vs 1/438 [0.2%]; P=.01). Conclusions In patients with familial hypercholesterolemia, pactimibe had no effect on atherosclerosis as assessed by changes in maximum CIMT compared with placebo but was associated with an increase in mean CIMT as well as increased incidence of major cardiovascular events.